ERC-BELGIUM S.A.
Epitopoietic Research Corporation (ERC-Belgium SA) is a clinical stage emerging Biopharmaceutical Company developing a safe, highly effective approach for the treatment of cancer, particularly cancers of the brain. ERC has built a network of leading neuro-oncologists in several countries in the world, among others in the US and Europe to propel its immunotherapies through clinical development and to market. ERC’s regimen of therapeutic vaccines has shown early promise in patients suffering from recurrent Glioblastoma multiforme (GBM), the deadliest of brain cancers.
ERC-BELGIUM S.A.
Industry:
Biotechnology
Address:
Gembloux, Namur, Belgium
Country:
Belgium
Website Url:
http://www.erc-immunotherapy.com
Status:
Active
Contact:
+32 81 72 86 10
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Nginx Microsoft Exchange Online Office 365 Mail
Similar Organizations
NovaRx
NovaRx Corporation is a clinical-stage biopharmaceutical company.
Official Site Inspections
http://www.erc-immunotherapy.com
- Host name: 206.81.12.176
- IP address: 206.81.12.176
- Location: North Bergen United States
- Latitude: 40.793
- Longitude: -74.0247
- Metro Code: 501
- Timezone: America/New_York
- Postal: 07047
More informations about "ERC-Belgium S.A."
ERC - Epitopoietic Research Corporation
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme …See details»
Executive board | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Epitopoietic Research Corporation - Wikipedia
Epitopoietic Research Corporation (ERC) is a Belgian Pharmaceutical company that is specialized in the development of ERC1671 (Gliovac, Sitooiganap (EU)), a treatment for Glioblastoma multiforme, which is the most aggressive form of brain cancer. In 2019 ERC provided treatment under the US Federal Right-to-try law. See details»
Contact | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Investors | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
ERC-Belgium S.A. - Crunchbase Company Profile & Funding
ERC has built a network of leading neuro-oncologists in several countries in the world, among others in the US and Europe to propel its immunotherapies through clinical development and …See details»
ERC Immunotherapy - Company Profile - Tracxn
Jan 17, 2025 ERC Immunotherapy (Epitopoietic Research Corporation) is a Belgian, clinical-stage biopharma developing Allogenic-autologous immunotherapy vaccine for Glioblastoma …See details»
Executive Management | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Epitopoietic Research Corporation - Facebook
Epitopoietic Research Corporation. 110 likes. ERC-ImmunotherapySee details»
Doctors | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with Glioblastoma multiforme …See details»
ERC Granted FDA Fast Track Designation for Sitoiganap in
ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track …See details»
Endothelial immunosuppressive mystery genes for alternative ...
Oct 24, 2022 Compared to my previous Advanced ERC grants, this proposal is fundamentally different not only concerning its topic but also regarding its ambition to offer greater societal …See details»
Gliovac/ERC1671 | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
ERC Launches Development Program for Novel Cell-Based
Apr 9, 2020 ERC is now applying its world leading immunotherapy technology to infectious diseases such as SARS-Cov-2, Ebola and other virus without any efficient treatment or …See details»
Milestone achievements | ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
ERC Right To Try Policy 15JULY2019 - erc-immunotherapy.com
5.2.1.ERC by email at medicalaffairs@erc-immunotherapy.com 5.3. Submissions of the Right-to-Try request form shall be sent to the email address noted in the form, for review and …See details»
News - ERC
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»
Endocrine side effects of cancer immunotherapy
Immune checkpoint inhibitors have recently become a cornerstone for the treatment of different advanced cancers. These drugs, represented mainly by monoclonal antibodies anti-cytotoxic T …See details»
Scientists rearing thousands of maggots for treating wounds - The …
5 days ago Biotherapy, also known as immunotherapy, uses substances derived from living organisms to treat diseases and is thus important in management of such wounds. Be part of …See details»
News | ERC - erc-immunotherapy.com
ERC is a clinical stage emerging Bio-pharmaceutical Company developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the …See details»